MedTrace Logo

Studying Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers

NCT00897455 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 10000

Last updated 2011-03-23

No results posted yet for this study

Summary

RATIONALE: Studying samples of DNA in the laboratory from women who are BRCA1/BRCA2 mutation carriers may help doctors learn more about cancer and identify biomarkers related to cancer.

PURPOSE: This research study is looking at breast cancer risk in women who are BRCA1/BRCA2 mutation carriers.

Conditions

Interventions

GENETIC

DNA analysis

GENETIC

mutation analysis

GENETIC

polymorphism analysis

OTHER

laboratory biomarker analysis

PROCEDURE

evaluation of cancer risk factors

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Gynecologic Oncology Group

    lead NETWORK

Principal Investigators

  • Mark H. Greene, MD · Clinical Genetics Branch

  • Michael Birrer, MD, PhD · NCI - Cell and Cancer Biology Branch

  • Phuong Mai, MD · Clinical Genetics Branch

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00897455 on ClinicalTrials.gov